Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma

American Journal of Hematology

Volumn 84, Issue 7, 2009, Pages 401-407

  Peng, Kah Whye ^a   Dogan, Ahmet ^a   Vrana, Julie ^a   Liu, Chunsheng ^a   Ong, Hooi T ^a   Kumar, Shaji ^a   Dispenzieri, Angela ^a   Dietz, Allan B ^a   Russell, Stephen J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD163 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; S100 ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITE; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE; MACROPHAGE; MEASLES VIRUS; MONOCYTE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR LOCALIZATION; VIROTHERAPY; XENOGRAFT;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE MARROW CELLS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MACROPHAGES; MEASLES; MEASLES VIRUS; MICE; MICE, SCID; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PLASMACYTOMA; STROMAL CELLS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HETEROLOGOUS;

EID: 67649700427     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21444     Document Type: Article

References (41)

1. Kyle RA. Multiple myeloma: An odyssey of discovery. Br J Haematol 2000; 111:1035-1044. (Pubitemid 32104913)
2. Rosinol L, Blade J, Esteve J, et al. Smoldering multiple myeloma: Natural history and recognition of an evolving type. Br J Haematol 2003;123:631-636. (Pubitemid 37468059)
3. Said JW, Rettig MR, Heppner K, et al. Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. Blood 1997;90:4278-4282. (Pubitemid 27508433)
4. Hideshima T, Mitsiades C, Tonon G, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 2007;7:585-598.
5. Kukreja A, Hutchinson A, Dhodapkar K, et al. Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 2006;203:1859-1865. (Pubitemid 44188460)
6. Roodman GD. Myeloma bone disease: Pathogenesis and treatment. Oncology (Williston Park) 2005;19:983-984, 986.
7. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-2216. (Pubitemid 34753592)
8. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 2002;196:254-265. (Pubitemid 34189413)
9. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78. (Pubitemid 38082155)
10. Ohno S, Suzuki N, Ohno Y, et al. Tumor-associated macrophages: Foe or accomplice of tumors? Anticancer Res 2003;23:4395-4409.
11. Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006;66:605-612. (Pubitemid 43165918)
12. Sica A, Schioppa T, Mantovani A, et al. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur J Cancer 2006;42:717-727.
13. Ishigami S, Natsugoe S, Tokuda K, et al. Tumor-associated macrophage (TAM) infiltration in gastric cancer. Anticancer Res 2003;23:4079-4083. (Pubitemid 37474368)
14. Dirkx AE, Oude Egbrink MG, Wagstaff J, et al. Monocyte/macrophage infiltration in tumors: Modulators of angiogenesis. J Leukoc Biol 2006;80:1183-1196. (Pubitemid 44904956)
15. Vallario A, Chilosi M, Adami F, et al. Human myeloma cells express the CD38 ligand CD31. Br J Haematol 1999;105:441-444. (Pubitemid 29232168)
16. Bhatti SS, Kumar L, Dinda AK, et al. Prognostic value of bone marrow angiogenesis in multiple myeloma: Use of light microscopy as well as computerized image analyzer in the assessment of microvessel density and total vascular area in multiple myeloma and its correlation with various clinical, histological, and laboratory parameters. Am J Hematol 2006;81:649-656. (Pubitemid 44306822)
17. Scavelli C, Nico B, Cirulli T, et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 2007;27:663-674.
18. Stief AE, McCart JA. Oncolytic virotherapy for multiple myeloma. Expert Opin Biol Ther 2008;8:463-473. (Pubitemid 351570410)
19. Deng H, Tang N, Stief AE, et al. Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus. Leukemia 2008;22: 2261-2264.
20. Au GG, Lincz LF, Enno A, et al. Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma. Br J Haematol 2007;137:133-141. (Pubitemid 46474719)
21. Lichty BD, Stojdl DF, Taylor RA, et al. Vesicular stomatitis virus: A potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004;15:821-831. (Pubitemid 39244837)
22. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98:2002-2007.
23. Dingli D, Peng KW, Harvey ME, et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004;103:1641-1646. (Pubitemid 38268954)
24. Ong HT, Timm MM, Greipp PR, et al. Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol 2006;34:713-720. (Pubitemid 43737093)
25. Myers RM, Greiner SM, Harvey ME, et al. Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. Clin Pharmacol Ther 2007;82:700-710. (Pubitemid 350114828)
26. Thorne SH, Contag CH. Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther 2008;15:753-758. (Pubitemid 351627358)
27. Munguia A, Ota T, Miest T, et al. Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth. Gene Ther 2008;15:797-806. (Pubitemid 351627364)
28. Power AT, Wang J, Falls TJ, et al. Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther 2007;15:123-130. (Pubitemid 46043657)
29. Ong HT, Hasegawa K, Dietz AB, et al. Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther 2007;14:324-333. (Pubitemid 46231926)
30. Iankov ID, Blechacz B, Liu C, et al. Infected cell carriers: A new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther 2007;15:114-122. (Pubitemid 46043656)
31. Mantovani A, Allavena P, Sozzani S, et al. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14:155-160. (Pubitemid 38586740)
32. Mantovani A, Bottazzi B, Colotta F, et al. The origin and function of tumorassociated macrophages. Immunol Today 1992;13:265-270.
33. Arendt BK, Velazquez-Dones A, Tschumper RC, et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002;16:2142-2147. (Pubitemid 35203460)
34. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005;23:344-346. (Pubitemid 41443435)
35. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: Myeloma-osteoclast interactions as a model. Cancer Res 2004;64: 2016-2023. (Pubitemid 38339448)
36. Anderson KC. Targeted therapy of multiple myeloma based upon tumormicroenvironmental interactions. Exp Hematol 2007;35:155-162. (Pubitemid 46427993)
37. Dogan A, Burke JS, Goteri G, et al. Micronodular T-cell/histiocyte-rich large B-cell lymphoma of the spleen: Histology, immunophenotype, and differential diagnosis. Am J Surg Pathol 2003;27:903-911. (Pubitemid 36758893)
38. Dietz AB, Bulur PA, Emery RL, et al. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers. Transfusion 2006;46:2083-2089. (Pubitemid 44813725)
39. Dietz AB, Bulur PA, Erickson MR, et al. Optimizing preparation of normal dendritic cells and bcr-abl1 mature dendritic cells derived from immunomagnetically purified CD141 cells. J Hematother Stem Cell Res 2000;9:95-101. (Pubitemid 30159507)
40. Dietz AB, Padley DJ, Butler GW, et al. Clinical-grade manufacturing of DC from CD141 precursors: Experience from phase I clinical trials in CML and malignant melanoma. Cytotherapy 2004;6:563-570. (Pubitemid 40028915)
41. Duprex WP, McQuaid S, Roscic-Mrkic B, et al. In vitro and in vivo infection of neural cells by a recombinant measles virus expressing enhanced green fluorescent protein. J Virol 2000;74:7972-7979.